Nikita Shah - 01 Mar 2024 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Signature
/s/ Denis Butkovic, Attorney-in-Fact
Issuer symbol
AMRX
Transactions as of
01 Mar 2024
Net transactions value
-$308,049
Form type
4
Filing time
05 Mar 2024, 16:35:17 UTC
Previous filing
29 Feb 2024
Next filing
16 Aug 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMRX Class A Common Stock Options Exercise +28,957 +8.6% 365,879 01 Mar 2024 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability $83,040 -15,181 -4.1% $5.47 350,698 01 Mar 2024 Direct F3
transaction AMRX Class A Common Stock Options Exercise +36,232 +10% 386,930 03 Mar 2024 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability $99,297 -18,153 -4.7% $5.47 368,777 03 Mar 2024 Direct F3
transaction AMRX Class A Common Stock Options Exercise +45,871 +12% 414,648 03 Mar 2024 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability $125,712 -22,982 -5.5% $5.47 391,666 03 Mar 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Restricted Stock Units Options Exercise $0 -28,957 -50% $0.000000 28,958 01 Mar 2024 Class A Common Stock 28,957 Direct F2, F4
transaction AMRX Restricted Stock Units Options Exercise $0 -36,232 -33% $0.000000 72,464 03 Mar 2024 Class A Common Stock 36,232 Direct F2, F5
transaction AMRX Restricted Stock Units Options Exercise $0 -45,871 -25% $0.000000 137,615 03 Mar 2024 Class A Common Stock 45,871 Direct F2, F6
transaction AMRX Restricted Stock Units Award $0 +143,519 $0.000000 143,519 04 Mar 2024 Class A Common Stock 143,519 Direct F2, F7
transaction AMRX Performance-Based Restricted Stock Units Award $0 +287,038 $0.000000 287,038 04 Mar 2024 Class A Common Stock 287,038 Direct F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3 Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4 March 1, 2021, the reporting person was granted 115,830 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F5 On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F6 On March 3, 2023, the reporting person was granted 183,486 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F7 The restricted stock units vest in four equal installments beginning on March 4, 2025.
F8 Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F9 Represents a performance-based restricted stock unit grant of 143,519 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period.